Subject: Financing Business: Liposome Co. 
Date: Published: 3/28/91 (27 lines)
Source: Wall Street Journal. Copyright Dow Jones & Co. Inc.

    Financing Business:
    Liposome Co. 

    LIPOSOME Co. (Princeton, N. J.)  said it completed a public
 offering of 3.5 million shares at $10.75 each, raising $37.6
 million for use in developing an AIDS treatment.  The
 biotechnology company said the underwriters, Oppenheimer &
 Co. and Hambrecht & Quist Inc., were granted options to buy
 525,000 more shares to cover overallotments, if any.  Liposome
 shares closed yesterday at $11.375, up 12.5 cents, in
 national over-the-counter trading.  Volume was heavy, over 1.7
 million shares.  Liposome said the funds will be used
 primarily for development and clinical testing of TLC G-65.
 The drug, an aminoglycoside, is currently in clinical trials
 for treating a common infection in people with acquired
 immune deficiency syndrome.  The infection, mycobacterium
 avium-intracellulare, eventually attacks about 30% to 50% of
 AIDS patients, Liposome said.

[This article is made available here by Dow Jones Co. for the 
personal and non-commercial use of callers to this bbs, in the 
hope that it will be of some help to those who are suffering 
from the disease and others who are seeking to help them.]